# Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

> **NCT01058616** · PHASE1 · COMPLETED · sponsor: **Lytix Biopharma AS** · enrollment: 14 (actual)

## Conditions studied

- Cancer With Transdermal Accessible Tumour

## Interventions

- **DRUG:** LTX-315 (Oncopore™)

## Key facts

- **NCT ID:** NCT01058616
- **Lead sponsor:** Lytix Biopharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058616, "Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01058616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*